Researchers at The Hong Kong Polytechnic University (PolyU) have developed an imaging biomarker, the Tumour Heterogeneity Index (THI), which enables noninvasive assessment of breast cancer patients' response to AKT inhibitors before treatment, helping clinicians identify patients most likely to benefit from therapy. The study found that patients with a high THI achieved an estimated pathological complete response (pCR) rate of 56.1%, significantly higher than that of patients with a low THI. The technology could help patients receive the most appropriate treatment at an earlier stage, reduce unnecessary side effects and enable clinicians to better tailor treatment strategies to individual patients.
❓ Unknown
New Imaging Biomarker Enhances Breast Cancer Treatment Efficacy
Just now
November 2, 2026
1 min read
📰 Medical Xpress
📋 Key Takeaway
Researchers at The Hong Kong Polytechnic University have developed the Tumour Heterogeneity Index (THI), an imaging biomarker that assesses breast cancer patients' response to AKT inhibitors noninvasively. This advancement could lead to more personalized and effective cancer treatments, potentially impacting healthcare strategies in countries like Iran.
🔍 Quick Context Guide
💡 Bottom Line:
The development of the THI could revolutionize breast cancer treatment by enabling more effective and tailored therapies.
👥 Key Players
The Hong Kong Polytechnic University
MENTIONED
Research institution
"Significant in advancing medical research and technology that can influence treatment protocols globally, including in Iran."
Clinicians and oncologists
MENTIONED
Healthcare providers
"They will utilize the THI to improve patient outcomes, potentially impacting cancer treatment strategies in Iran."
📰 What Happened
Researchers developed a new imaging biomarker called the Tumour Heterogeneity Index (THI) that helps assess breast cancer patients' responses to AKT inhibitors noninvasively. This advancement allows for more personalized treatment plans based on individual patient responses.
- Patients with a high THI had a 56.1% pathological complete response rate.
- The THI enables earlier identification of patients likely to benefit from specific therapies.
💡 Why It Matters
🇮🇷 For Iran: This technology could enhance breast cancer treatment strategies in Iran, where healthcare resources are limited and personalized medicine is increasingly important.
🌍 Regional: Improved cancer treatment technologies could lead to better health outcomes across the Middle East, where cancer rates are rising.
🌐 International: This research may influence global cancer treatment protocols and highlight the importance of personalized medicine in oncology.
📚 Background
Breast cancer is a leading cause of cancer-related deaths worldwide, and advancements in treatment personalization are crucial for improving patient outcomes. AKT inhibitors are a class of drugs used in cancer therapy that target specific pathways involved in tumor growth.
Breast cancer treatment
Personalized medicine
📡 Source:
NEUTRAL
📊 Confidence:
70%
The information comes from a research institution, which typically aims to present findings objectively.
🏷️ Entities Mentioned
🌐
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%
📰 Related Coverage
Just now •
IRGC Navy Reports Explosions of Two Oil Tankers in Strait of Hormuz
16 min ago •
Gulf Region Prepares for Potential US-Iran Conflict
17 min ago •
Trump Claims to Have Had Discussion with Netanyahu About Iran
20 min ago •
Gulf Leaders Gather in Qatar to Prevent Escalation of U.S.-Iran Tensions
23 min ago •